Dr Reddys Laboratories (RDY) Gross Profit (2009 - 2026)

Dr Reddys Laboratories has reported Gross Profit for 18 years, with the latest figure at $396.5 million in Q2 2026.

• On a quarterly basis, Gross Profit fell 30.21% year-over-year to $396.5 million in Q2 2026; TTM through Jun 2026 was $1.8 billion, a 18.66% decrease from a year earlier, with the FY2026 full-year figure at $1.9 billion, down 15.29% from the prior year.
• Gross Profit was $396.5 million for Q2 2026 at Dr Reddys Laboratories, up from $368.6 million in the prior quarter.
• The five-year high for Gross Profit was $581.0 million in Q4 2024, with the low at $337.3 million in Q2 2022.
• Average Gross Profit over 5 years is $487.0 million, with a median of $493.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Gross Profit soared 44.1% in 2023, then sank 32.47% in 2026.
• Over 5 years, Gross Profit stood at $439.0 million in 2022, then climbed by 15.46% to $506.9 million in 2023, then grew by 14.62% to $581.0 million in 2024, then declined by 9.53% to $525.6 million in 2025, then dropped by 24.56% to $396.5 million in 2026.
• The last three Gross Profit figures came in at $396.5 million (Q2 2026), $368.6 million (Q1 2026), and $525.6 million (Q4 2025), per Business Quant data.